aTyr Pharma gets more time on Nasdaq listing

aTyr Pharma, Inc. received an additional 180-day period from Nasdaq to regain compliance with the exchange’s minimum bid price requirement for continued listing.

Rhea-AI Filing Summary

aTyr Pharma, Inc. received an additional 180-day period from Nasdaq to regain compliance with the exchange’s minimum bid price requirement for continued listing. The company now has until November 30, 2026 for its stock to close at or above $1.00 for at least 10 consecutive business days.

The extension was granted because aTyr meets other Nasdaq Capital Market listing standards, including market value of publicly held shares, and has stated its intention to cure the deficiency, potentially through a reverse stock split. The company’s shares remain listed while it monitors its stock price and evaluates options.

Positive

• None.

Negative

• Heightened delisting risk from prolonged sub‑$1 share price – aTyr Pharma remains out of compliance with Nasdaq’s minimum bid price rule and has only until November 30, 2026 to cure the deficiency or face a potential delisting determination.

Insights

Equity market and listing standards analyst

Nasdaq grants aTyr more time to fix its sub‑$1 share price.

aTyr Pharma has received a second 180-day period to meet Nasdaq’s $1.00 minimum bid price rule. The shares stay on the Nasdaq Capital Market while the company works to get its stock trading above that threshold for the required stretch of days.

The extension reflects that aTyr still satisfies other Nasdaq initial listing standards, such as market value of publicly held shares. However, failing to reach the bid price requirement by November 30, 2026 would trigger a delisting notice, although an appeal to a hearings panel would be available.

The company explicitly mentions a potential reverse stock split as a cure, which is a common mechanical tool to lift the per-share price without changing overall market value. Subsequent company communications will clarify whether and when such a corporate action is pursued before the new compliance deadline.

8-K Event Classification

Item 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

1 item

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Securities

The company received a delisting notice, failed to satisfy a continued-listing rule or standard, or transferred its listing.

Key Figures

Minimum bid price requirement: $1.00 per share Initial compliance period: 180 calendar days Second compliance deadline: November 30, 2026 +2 more

5 metrics

Minimum bid price requirement $1.00 per share Nasdaq Listing Rule 5550(a)(2) threshold

Initial compliance period 180 calendar days From December 4, 2025 to June 2, 2026

Second compliance deadline November 30, 2026 End of additional 180-day period to regain compliance

Required compliant trading period 10 consecutive business days Closing bid price at or above $1.00 per share

Possible extended observation window Up to 20 business days Nasdaq staff discretion for confirming compliance

Key Terms

Nasdaq Listing Rule 5550(a)(2), minimum bid price requirement, market value of publicly held shares, reverse stock split, +1 more

5 terms

Nasdaq Listing Rule 5550(a)(2) regulatory

"the minimum closing bid price required by the continued listing requirements of Nasdaq Listing Rule 5550(a)(2)"

minimum bid price requirement financial

"to regain compliance with the minimum bid price requirement by having shares of the Company’s common stock maintain a minimum closing bid price"

A minimum bid price requirement is a rule that a stock must trade above a set price for a specified period to stay listed on an exchange. It matters to investors because falling below that threshold can trigger warnings or removal from the exchange, which can cut liquidity, reduce visibility, and often lead to sharper declines in share value—think of it like a venue’s minimum dress code that, if not met, can bar a performer from the stage.

market value of publicly held shares financial

"based on the Staff’s determination of the Company meeting the continued listing requirement for market value of publicly held shares"

The market value of publicly held shares is the total dollar worth of a company’s shares that are available to outside investors, calculated by multiplying the current market price by the number of shares held by the public (the “float”). It matters because it tells investors how much of the company is actually tradable and how the market is pricing that tradable portion—like a price tag on the items on a store shelf, it affects liquidity, volatility and how easy it is to buy or sell a meaningful stake.

reverse stock split financial

"its intention to cure the deficiency during the second compliance period, by effecting a reverse stock split, if necessary"

A reverse stock split reduces a company's number of outstanding shares while raising the price per share proportionally, so the total value of each investor's holding is unchanged; a 1-for-10 split turns 100 shares worth $1 each into 10 shares worth $10 each. Companies often do this to regain compliance with an exchange's minimum price rule or to attract investors who avoid very low-priced stocks.

hearings panel regulatory

"the Company may appeal the delisting determination to a hearings panel pursuant to the procedures set forth"

A hearings panel is a review body at a stock exchange that hears the case when the exchange has decided a company no longer qualifies to keep its shares listed. The company presents a plan to regain compliance, and the panel decides whether the listing continues, on what conditions, and for how long. The decision can keep a stock trading or end its listing.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What Nasdaq issue did aTyr Pharma (ATYR) disclose in this 8-K?

aTyr Pharma disclosed it remains noncompliant with Nasdaq’s $1.00 minimum bid price rule. Nasdaq granted an additional 180 days to regain compliance, keeping the stock listed on the Nasdaq Capital Market during this second grace period.

How long does aTyr Pharma have to regain Nasdaq bid price compliance?

aTyr Pharma now has until November 30, 2026 to regain compliance. Its common stock must close at or above $1.00 per share for at least 10 consecutive business days during this second 180-day period.

What happens if aTyr Pharma fails to meet Nasdaq’s bid price rule by November 30, 2026?

If aTyr Pharma does not regain compliance by November 30, 2026, Nasdaq staff will notify the company that its common stock is subject to delisting. aTyr may then appeal the delisting determination to a Nasdaq hearings panel under applicable procedures.

Why did Nasdaq grant aTyr Pharma an additional 180-day compliance period?

Nasdaq granted an extra 180 days because aTyr Pharma meets all initial listing standards for the Nasdaq Capital Market, except the minimum bid price. The company also notified Nasdaq in writing of its intention to cure the deficiency during this second period.

What steps might aTyr Pharma take to fix its Nasdaq bid price deficiency?

aTyr Pharma indicated it will monitor its share price and evaluate available options to regain compliance, including a potential reverse stock split. Such a split would reduce shares outstanding and typically increase the per-share trading price mechanically.

Does the Nasdaq compliance extension affect aTyr Pharma’s current listing status?

The extension has no immediate impact on aTyr Pharma’s listing. Its common stock continues to trade on the Nasdaq Capital Market while the company attempts to meet the $1.00 minimum bid price requirement within the new compliance period.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/08/2026 - 04:04 PM EDT Learn about SEC filing dates

false000133997000013399702026-06-032026-06-03

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 3, 2026

ATYR PHARMA, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-37378		20-3435077
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)
10240 Sorrento Valley Road, Suite 300 San Diego, CA				92121
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s telephone number, including area code: (858) 731-8389

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.001 per share	ATYR	The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

As previously disclosed, on December 4, 2025, aTyr Pharma, Inc. (the “Company”) received a deficiency notice (the “Notice”) from the listing qualifications staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days preceding the date of the Notice, the bid price of the Company’s common stock had closed below $1.00 per share, the minimum closing bid price required by the continued listing requirements of Nasdaq Listing Rule 5550(a)(2). The Notice had no immediate effect on the listing of the Company’s common stock on The Nasdaq Capital Market. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company had 180 calendar days, or until June 2, 2026 (the “Initial Compliance Date”), to regain compliance with the minimum bid price requirement by having shares of the Company’s common stock maintain a minimum closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days before the Initial Compliance Date.

On June 3, 2026, the Company received a letter from the Staff (the “Letter”) notifying the Company that the Company is eligible for an additional 180-day period, or until November 30, 2026 (the “Compliance Date”), to regain compliance, based on the Staff’s determination of the Company meeting the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the minimum bid price requirement, and the Company’s written notice to Nasdaq of its intention to cure the deficiency during the second compliance period, by effecting a reverse stock split, if necessary. The Letter has no immediate impact on the listing of the Company’s common stock on The Nasdaq Capital Market. If at any time during the second compliance period the closing bid price of the Company’s common stock is at least $1.00 per share for a minimum of 10 consecutive business days (which may be extended to be a period of up to 20 consecutive business days in the discretion of the Staff), Nasdaq will provide the Company with written confirmation of compliance.

If the Company does not regain compliance by the Compliance Date, the Staff will provide written notification that the Company’s common stock is subject to delisting. At that time, the Company may appeal the delisting determination to a hearings panel pursuant to the procedures set forth in the applicable Nasdaq listing rules. However, there can be no assurance that, if the Company receives a delisting notice and appeals the delisting determination by Nasdaq to the panel, such appeal would be successful.

The Company intends to actively monitor the closing bid price of its common stock between now and the Compliance Date and, as appropriate, will evaluate available options to resolve the deficiency and regain compliance with the minimum bid price requirement.

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ATYR PHARMA, INC.
	By:	/s/ Jill M. Broadfoot
		Jill M. Broadfoot
		Chief Financial Officer
Date: June 8, 2026

3

Filing Exhibits & Attachments

1 document

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 25.4 KB